Fortitude Family Office’s Ironwood Pharmaceuticals IRWD Stock Holding History

Fortitude Family Office’s Portfolio IRWD Stock Details IRWD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.69K	Buy	+1,114	New	+$4.29K	﹤0.01%	1106
2025 Q2	–	Sell	-610	Closed	-$897	–	2078
2025 Q1	$897	Hold	610	–	–	﹤0.01%	1030
2024 Q4	$2.7K	Buy	+610	New	+$2.48K	﹤0.01%	979

Other funds holding IRWD

WCM

Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

CAMG

CWA Asset Management Group Naples, Florida $3.28B AUM 34.07% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

MFG

Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return

PFSRSONJ

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Grimes & Company Westborough, Massachusetts $4.62B AUM 29.71% 1-Year Est. Return

MFG

Magnus Financial Group New York $1.41B AUM 23.4% 1-Year Est. Return

NAM

NorthCrest Asset Manangement Plymouth, Minnesota $3.89B AUM 40.33% 1-Year Est. Return

Fortitude Family Office's IRWD Position: Q2 2026 in Review

Fortitude Family Office opened a new position in Ironwood Pharmaceuticals (IRWD) in Q2 2026: 1,114 shares worth $4.69K. The stake represents ﹤0.01% of the portfolio and ranks #1106 among its holdings. This is a return to the name: Fortitude Family Office previously reported a position in IRWD as recently as Q1 2025.

Fortitude Family Office first reported a position in IRWD in Q4 2024 and has held it in 3 quarters since. 27 funds tracked by Wall St. Rank hold IRWD as of Q2 2026.

Fortitude Family Office held 1,114 shares of Ironwood Pharmaceuticals worth $4.69K as of Q2 2026.
Ironwood Pharmaceuticals was a new Fortitude Family Office position in Q2 2026.
Ironwood Pharmaceuticals made up ﹤0.01% of Fortitude Family Office's portfolio in Q2 2026, its #1106 holding.
Fortitude Family Office first reported a position in Ironwood Pharmaceuticals in Q4 2024 and has held it in 3 quarters since.
27 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q2 2026.

Based on Fortitude Family Office's 13F filing for Q2 2026, filed 20 Jul 2026.